The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Genital Diseases, Female

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Genital Diseases, Female


High impact information on Genital Diseases, Female


Chemical compound and disease context of Genital Diseases, Female

  • Monthly implant of luteinizing hormone-releasing hormone agonist: a practical therapeutic approach for sex-steroid dependent gynecologic diseases [8].
  • Samples of cervical tissue were obtained from women immediately following term delivery from spontaneous labor or oral PGE2-induced labor and from a small nunber of nonpregnant women in the reproductive years undergoing hysterectomy for benign gynecologic disease [9].
  • To evaluate the usefulness of the plasma dehydroepiandrosterone (DHEA)-to-cortisol ratio (D/C) and the plasma aldosterone-to-plasma renin activity ratio (ALDO/PRA) as indicators of stress, we first monitored changes in these ratios associated with surgery in 13 patients who were healthy except for their localized gynecologic diseases [10].
  • No significant difference was found when arterial and venous levels were compared and there was no difference in venous PGE levels when subjects with cancer were compared to patients with benign gynecologic disease [11].
  • Urinary gonadotropin peptide (UGP) was measured in 866 urines from normal women and women with benign and malignant gynecologic disease using the Triton UGP enzyme immunoassay [12].

Biological context of Genital Diseases, Female

  • SETTING: Department of Obstetrics and Gynecology, Shimane Medical University Hospital, Izumo, Japan. PATIENT(S): Two hundred forty-five Japanese women with endocrine disorders and/or gynecologic disease and 153 healthy, nonpregnant, fertile Japanese women [13].
  • We investigated serum CA 125 levels in 120 patients with benign gynecologic disease, and examined variations in CA 125 levels during the menstrual cycle in six normally cycling women [14].

Anatomical context of Genital Diseases, Female


Gene context of Genital Diseases, Female


Analytical, diagnostic and therapeutic context of Genital Diseases, Female

  • The concentration of TATI was determined by radioimmunoassay in the urine of 148 patients with various forms of gynecologic malignancy and in a reference population consisting of 98 patients with non-malignant gynecologic disease, and also in 40 patients with severe infections or inflammatory disease [6].


  1. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Chatterjee, M., Mohapatra, S., Ionan, A., Bawa, G., Ali-Fehmi, R., Wang, X., Nowak, J., Ye, B., Nahhas, F.A., Lu, K., Witkin, S.S., Fishman, D., Munkarah, A., Morris, R., Levin, N.K., Shirley, N.N., Tromp, G., Abrams, J., Draghici, S., Tainsky, M.A. Cancer Res. (2006) [Pubmed]
  2. Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality. Fornander, T., Rutqvist, L.E., Cedermark, B., Glas, U., Mattsson, A., Skoog, L., Somell, A., Theve, T., Wilking, N., Askergren, J. J. Clin. Oncol. (1991) [Pubmed]
  3. Tumor-associated antigens in cervical cancer tissues and in sera from patients with cervical cancer or with head and neck cancer. Ibrahim, A.N., Robinson, R.A., Marr, L., Abdelal, A.T., Nahmias, A.J. J. Natl. Cancer Inst. (1979) [Pubmed]
  4. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer. Kobayashi, H., Terao, T., Kawashima, Y. J. Clin. Oncol. (1991) [Pubmed]
  5. Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Porcile, C., Bajetto, A., Barbieri, F., Barbero, S., Bonavia, R., Biglieri, M., Pirani, P., Florio, T., Schettini, G. Exp. Cell Res. (2005) [Pubmed]
  6. Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy. Huhtala, M.L., Kahanpää, K., Seppälä, M., Halila, H., Stenman, U.H. Int. J. Cancer (1983) [Pubmed]
  7. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Baron, A.T., Boardman, C.H., Lafky, J.M., Rademaker, A., Liu, D., Fishman, D.A., Podratz, K.C., Maihle, N.J. Cancer Epidemiol. Biomarkers Prev. (2005) [Pubmed]
  8. Monthly implant of luteinizing hormone-releasing hormone agonist: a practical therapeutic approach for sex-steroid dependent gynecologic diseases. Lemay, A. Fertil. Steril. (1987) [Pubmed]
  9. Reduction of the stretch modulus of human cervical tissue by prostaglandin E2. Conrad, J.T., Ueland, K. Am. J. Obstet. Gynecol. (1976) [Pubmed]
  10. Plasma dehydroepiandrosterone-to-cortisol ratios as an indicator of stress in gynecologic patients. Ozasa, H., Kita, M., Inoue, T., Mori, T. Gynecol. Oncol. (1990) [Pubmed]
  11. Plasma prostaglandins across the tumor bed of patients with gynecologic malignancy. Mortel, R., Allegra, J.C., Demers, L.M., Harvey, H.A., Trautlein, J., Nahhas, W., White, D., Gillin, M.A., Lipton, A. Cancer (1977) [Pubmed]
  12. Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies. Walker, R., Crebbin, V., Stern, J., Scudder, S., Schwartz, P. Anticancer Res. (1994) [Pubmed]
  13. Increased prevalence of luteinizing hormone beta-subunit variant in patients with premature ovarian failure. Takahashi, K., Ozaki, T., Okada, M., Kurioka, H., Kanasaki, H., Miyazaki, K. Fertil. Steril. (1999) [Pubmed]
  14. Serum CA 125 levels in patients with endometriosis: changes in CA 125 levels during menstruation. Masahashi, T., Matsuzawa, K., Ohsawa, M., Narita, O., Asai, T., Ishihara, M. Obstetrics and gynecology. (1988) [Pubmed]
  15. CA 125 in peritoneal fluid: reliable values at high dilutions. Barbati, A., Anceschi, M.M., Di Renzo, G.C., Cosmi, E.V. Obstetrics and gynecology. (1992) [Pubmed]
  16. Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecologic diseases. Guadagni, F., Marth, C., Zeimet, A.G., Ferroni, P., Spila, A., Abbolito, R., Roselli, M., Greiner, J.W., Schlom, J. Am. J. Obstet. Gynecol. (1994) [Pubmed]
  17. Carcinoembryonic antigen in patients with gynecologic malignancy. van Nagell, J.R., Meeker, W.R., Parker, J.C., Harralson, J.D. Cancer (1975) [Pubmed]
  18. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies. Suzuki, M., Ohwada, M., Sato, I., Nagatomo, M. Oncology (1995) [Pubmed]
  19. Immunochemical measurement and immunohistochemical detection of membrane-associated placental tissue protein 1. Shirotake, S., Inaba, N., Ohta, Y., Sato, N., Fukazawa, I., Takamizawa, H., Bohn, H. Chem. Pharm. Bull. (1989) [Pubmed]
  20. Conservative management of gynecologic diseases: insulin sensitizing agents in polycystic ovary syndrome. Diamanti-Kandarakis, E., Kandarakis, H.A. Ann. N. Y. Acad. Sci. (2003) [Pubmed]
WikiGenes - Universities